Lipoxygenase inhibitors induce arrest of tumor cells in S-phase of the cell cycle
Jazyk angličtina Země Slovensko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
12584583
Knihovny.cz E-zdroje
- MeSH
- antioxidancia farmakologie MeSH
- bromodeoxyuridin MeSH
- buněčné dělení účinky léků MeSH
- DNA nádorová metabolismus MeSH
- inhibitory lipoxygenas farmakologie MeSH
- kyselina arachidonová metabolismus MeSH
- kyselina nordihydroguaiaretová farmakologie MeSH
- lidé MeSH
- myši MeSH
- nádorové buňky kultivované účinky léků patologie MeSH
- propidium metabolismus MeSH
- replikace DNA MeSH
- S fáze účinky léků genetika MeSH
- techniky in vitro MeSH
- umbeliferony farmakologie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antioxidancia MeSH
- bromodeoxyuridin MeSH
- DNA nádorová MeSH
- esculetin MeSH Prohlížeč
- inhibitory lipoxygenas MeSH
- kyselina arachidonová MeSH
- kyselina nordihydroguaiaretová MeSH
- propidium MeSH
- umbeliferony MeSH
Inhibitors of the lipoxygenase pathway of arachidonic acid metabolism represent a potential anti-tumor drugs. These compounds have been found to inhibit the growth and induce the apoptosis of various tumor cells both in vitro and in vivo. In this study, the effects of the lipoxygenase inhibitors esculetin and nordihydroguaiaretic acid (NDGA) on the progression of the cell cycle were investigated in eight mammalian cell lines of different origin. Flow cytometric analyses of cell cycle distribution after staining of DNA with propidium iodide or 7-aminoactinomycin D and DNA synthesis using incorporation of 5-bromo-2'-deoxy-uridine showed that both esculetin and NDGA suppress cell growth by interrupting the progression of cells through S-phase that results in their accumulation in this phase of the cell cycle. The possible mechanisms of these effects and the significance of the findings for the improvement of anticancer therapy targeted on cell cycle is discussed.